Neurobehavioral Mechanisms of Decisions to Smoke Marijuana and Cocaine in Humans

描述（由申请人提供）：近年来，在理解目标导向决策的神经生物学方面取得了实质性进展。有证据表明，这种决定产生特定的神经激活模式，假设反映主观或目标值（GV）的编码，定义为可用选项的预测奖励值，在决策时以“共同货币”计算14，15。这些知识的许多收获都来自神经经济学学科。尽管这些研究结果与药物依赖性有明确的相关性，可以说是决策的病理学16，22，但对吸毒者做出的最临床相关决定的神经行为机制知之甚少：获得和使用药物的决定。本申请提出了两项平行的受试者内研究，研究了普通MJ和COC使用者在金钱和大麻（MJ~研究1），可卡因（COC~研究2）和可口食物（两项研究）之间选择时GV的神经编码，以及线索暴露对这些过程的影响。采用人类行为药理学，先进的功能磁共振成像方法和神经经济学的方法相结合，我们的目标是有助于了解神经行为机制的决定，使用药物与非药物奖励在经常吸毒者，知识，最终可以发挥核心作用，在制定干预措施，以防止这些决定。常规非寻求治疗的MJ（e4 x/周~ N=20）和COC（e2 x/周~ N=20）吸烟者将完成4天的住院方案，包括4个随机条件：1）中性线索后的药物与金钱选择~ 2）药物线索后的药物与金钱选择~ 3）中性线索后的食物与金钱选择~和4）食物线索后的食物与金钱选择。在fMRI任务中，将在药物/食物和金钱之间做出一系列选择，之后将随机选择一个选择进行实施，并相应地给予MJ，COC或食物。我们的目标是：1）表征药物或食物提供量与所做决定之间关系的神经介质2）研究药物选择与食物选择之间行为和神经GV信号的差异3）比较药物和食物线索对药物相对于食物选择期间行为和GV信号的影响。我们预计，腹内侧前额叶皮层（vmPFC）和纹状体中的信号传导将介导所有三种强化剂的数量与决策之间的关系。我们进一步假设，药物相关的决策，以及药物而不是食物线索后的决策，将涉及vmPFC和纹状体中定量更大的GV信号传导，被认为是灵长类动物大脑中的最终估价座位14，15。 这些研究的执行将与全面的培训计划相结合，包括Matlab编程，高级功能磁共振成像分析和神经经济学的教学培训，人类行为药理学和功能磁共振成像方法的指导阅读，以及国际公认的人类行为药理学专家团队的监督和监督（Haney和Foltin博士），高级功能磁共振成像分析（Lindquist博士），以及决策的神经生物学（Glimcher博士）。因此，拟议的完善的培训计划将为主要研究者Gill Bedi博士提供这些领域的高级技能，以启动一项独立的研究计划，利用人类行为药理学和先进的功能磁共振成像技术来调查有关药物成瘾的临床重要问题。Bedi博士拥有临床心理学的研究生培训和人类行为药理学的博士后培训，涉及非临床但非吸毒人群的非法药物挑战研究。她在早期职业研究者的出版物方面有着良好的记录，并证明了她有能力获得NIH的小额赠款资金，并在2011年获得了R 03和R21。虽然这一新兴的研究轨道预示着她的能力发展成为一个创造性和生产力的独立研究人员，保护的时间，培训和指导的研究经验，将提供根据这个K23奖是至关重要的，在她的职业生涯的这个时刻，让她完成过渡到完全独立的病人为导向的研究人员。Bedi博士的近期目标是发展人类行为药理学和fMRI分析方面的高级技能，这将使她能够获得独立的R 01资金。她的长期目标是在纽约州立精神病学研究所和哥伦比亚精神病学的物质使用研究中心内采用这些方法开展一系列有计划的研究。可用于支持Bedi博士作为研究人员发展的机构环境是世界上最好的，结合了国际知名的高级教师，年轻研究人员成功发展的既定历史，和世界一流的设施，包括医疗设施，以支持研究涉及大麻和可卡因吸烟自我管理和3 T研究-专用GE MR扫描仪，位于NYSPI MRI中心。因此，本申请提出了一个具有重大影响潜力的创新项目。它结合了专家指导和全面的培训，以促进早期职业研究人员的过渡，具有有前途的新兴出版物和小NIH赠款资金，以完全独立为以患者为导向的研究人员。

DESCRIPTION (provided by applicant): Recent years have seen substantial advances in understanding of the neurobiology of goal-directed decision making. There is evidence that such decisions produce specific neural activation patterns hypothesized to reflect encoding of subjective or goal values (GVs), defined as the predicted reward value of available options, calculated in a 'common currency' at the time of decision14,15. Many of these gains in knowledge are emerging from the discipline of neuroeconomics. Despite the clear relevance of these findings for drug dependence, arguably pathology of decision-making16, 22, little is known about the neurobehavioral mechanisms of the most clinically-relevant decisions made by drug users: decisions to obtain and use drugs. This application proposes two parallel within-subjects studies examining the neural encoding of GVs during choices between money and marijuana (MJ~ Study 1), cocaine (COC~ Study 2) and palatable food (both studies) in regular MJ and COC users, and the impact of cue exposure on these processes. Employing a combination of human behavioral pharmacology, advanced fMRI methods, and neuroeconomic approaches, we aim to contribute an understanding of the neurobehavioral mechanisms underlying decisions to use drugs versus non-drug rewards in regular drug users, knowledge that could ultimately play a central role in developing interventions to prevent these decisions. Regular non-treatment-seeking MJ (e4x/week~ N=20) and COC (e2x/week~ N=20) smokers will complete a 4-day inpatient protocol including 4 randomized conditions: 1) Drug versus money choices after neutral cues~ 2) Drug versus money choices after drug cues~ 3) Food versus money choices after neutral cues~ and 4) Food versus money choices after food cues. A range of choices between drug/food and money will be made in an fMRI task, after which one choice will be randomly selected for implementation, with MJ, COC or food administered accordingly. We aim to 1) characterize neural mediators of relationships between the amount of drug or food offered and the decisions made~ 2) Investigate differences in behavior and neural GV signals during choices about drug compared to choices about food~ and 3) Compare effects of drug and food cues on behavior and GV signals during choices about drugs relative to food. We anticipate that signaling in the ventromedial Prefrontal Cortex (vmPFC) and striatum will mediate relationships between the amount of all three rein forcers offered and decisions made. We further hypothesize that drug-related decisions, and decisions after drug but not food cues, will involve quantitatively greater GV signaling in vmPFC and striatum, thought to be the final seat of valuation in the primate brain14,15. Execution of these studies will be combined with a comprehensive training program that includes didactic training in Matlab programming, advanced fMRI analysis, and neuroeconomics, guided readings in human behavioral pharmacology and fMRI methods, and supervision and oversight by a team of internationally- recognized experts in human behavioral pharmacology (Drs. Haney and Foltin), advanced fMRI analysis (Dr. Lindquist), and the neurobiology of decision-making (Dr. Glimcher). The well developed training plan proposed will therefore provide the Principal Investigator, Dr. Gill Bedi, with the advanced-level skills in these areas to initiate an independent research program, using human behavioral pharmacology and advanced fMRI skills to investigate clinically-important questions about drug addiction. Dr. Bedi has graduate training in clinical psychology and postdoctoral training in human behavioral pharmacology involving illicit drug challenge studies in non-clinical, but not drug-using, populations. She has a strong track record of publication for an early career investigator, and has demonstrated capacity to obtain NIH funding for small grants, having been awarded an R03 and a R21 in 2011. While this emerging research track bodes extremely well for her capacity to develop into a creative and productive independent researcher, the protected time, training, and mentored research experience that would be provided under this K23 award are critical at this juncture of her career to allow her to complete the transition to full independence as a patient-oriented researcher. Dr. Bedi's immediate goal is to develop advanced skills in human behavioral pharmacology and fMRI analysis that would allow her to obtain independent R01 funding. Her longer-term goal is to develop a programmatic line of research employing these methods within the Substance Use Research Center in New York State Psychiatric Institute and Columbia Psychiatry. The Institutional environment available to support Dr. Bedi's development as a researcher is among the best in the world, combining ready access to internationally-renowned senior faculty, an established history of successful development of young researchers, and world-class facilities including medical facilities to support studies involving marijuana and cocaine smoked self-administration and a 3T research-dedicated GE MR scanner housed in the NYSPI MRI Center. Thus, this application proposes an innovative project with the potential for substantial impact. It combines expert mentorship and comprehensive training to facilitate the transition of an early career researcher with a promising emerging track of publication and small NIH grant funding to full independence as a patient-oriented researcher.